Beautiful banking to grow smarter

Lyfegen Launches the World's Largest Database of Value-Based drug Agreements

Lyfegen and Switzerland’s EGK Insurance Partner to Reduce Prices for High-cost Drugs

A big win for value-based care: Medicare can now negotiate some drug prices

Medicare Part D redesign could reboot U.S. prescription drug market for cancer drugs, making pricing more value-based

Meet our new in-house detective: Hello to Alina Bratu!

Value-based drug agreements are easier when drug manufacturers and payers follow FDA communication guidelines

Federal Trade Commission inquiry could eventually lead to overhaul of prescription drug rebate system

Lyfegen Raises $8 Million to Drive Down Drug Costs and Help Patients Access Life-Saving Medications

After accelerated drug approval: Value-based drug pricing does the work of real-world data collection

The uphill battle for value-based drug pricing agreements may be coming to an end

Leveraging clinical- and cost-effectiveness data to inform drug pricing and reimbursement

Keeping our users happy everyday: Meet Liubov, our new quality assurance (QA) engineer

Indication-specific pricing to make inroads in the U.S.

Value-based pricing vs best price? Medicaid's best price problem

Biosimilars appear ready for prime time in the U.S. as reimbursement is increasingly value-based

How to overcome hurdles to implement value-based pricing

Hello to our new team member: Meet efficacy expert Anca Marin!

Who does it better? Assessing a value-based drug price in Europe vs the US

Could a value-based purchasing agreement with the U.S. Centers for Medicaid and Medicare Services have saved Aduhelm?

A new star in the Lyfegen sky: Meet Valeria Litfullina, our new front-end developer

Healthcare providers hold real-world evidence about a drug’s value. How to convince them to share the data?

U.S. Department of Health and Human Services’ Innovation Center Revamps Value-Based Payment Models

Do drug companies really want more competition? Value-based purchasing puts them to the test

Is this new drug worth the cost? Payers decide using value-based purchasing agreements

Changes in Medicaid’s Best Price Rule Likely to Boost Value-Based Purchasing Agreements

Industry experts agree outcome-based contracting is vital to the future of cell and gene therapies

Medicare needs authority to negotiate drug prices to support its value-based healthcare strategy

Lyfegen Welcomes Productivity Superstar Isabelle as Executive Assistant!

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!-duplicate-1

ICER: Hero or Villain in the Story of Value-Based Drug Pricing?

Bluebird Bio’s exiting the European market signals problems for cell and gene therapy market access

The Effect of Value-Based Drug Pricing on Patient Health Outcomes: More of what’s needed—Efficacy, Access, and Affordability

Former New York State Medicaid Director Jason Helgerson joins Lyfegen advisory board

CMA & Lyfegen Present Joint Value-Based Contracting Platform for Pharmacy at Medicaid’s Most Important Conference

Swiss health insurance Sympany implements Lyfegen Platform to efficiently execute complex value & data-driven agreements for high-priced medication.

The importance of working with Johnson & Johnson: An interview with our Lyfegen CEO & Founder, Girisha Fernando

How Far Would You go to Save Your Child?

How Lyfegen’s value-based contracting platform was inspired by Airbnb

A new face is on board! Welcome to Lyfegen, Tech-Guru Andrei

Breaking News: Lyfegen platform supports Johnson & Johnson to further drive value-based healthcare strategy

Our team is growing! Welcome to Lyfegen, Tech-Genius Giancarlo!

Nico Mros named Lyfegen’s Chief Customer Experience Officer (CXO)

Welcome to the Lyfegen Team, Mastermind-Developer, Thungu!

Welcome to the Lyfegen Team, Design-Superstar, Kateryna!

2021 brings great news as Lyfegen’s team continues to grow: Antti joins as Product Owner!

Lyfegen welcomes Frederico as Chief Technology Officer!

The tech team is growing at full-speed! Welcome to the Lyfegen team, tech-genius Dima!

At the forefront of value-based healthcare: Lyfegen and KPMG Switzerland release whitepaper together

The Tech Team Keeps Growing! Welcome to the Lyfegen Team, Analytical-Superstar, Pavlo!

Lyfegen Supports the Sustainable Development Goal #3: Good Health & Well Being

Lyfegen selected to join Groupe Mutuel’s acceleration program InnoPeaks!

Lyfegen is at the World Pharma Pricing, Evidence & Market Access Congress!

Our new tech superstar: Welcome to the Lyfegen team, Daniel!

Breaking News: Lyfegen Raises Additional CHF 2 Million to Advance Value-Based Healthcare Contracting

As Costs Continue to Rise, An Era of Change in the Swiss Healthcare System Approaches

Michael Porter’s VBHC Theory Explained by Lyfegen’s Customer Success Hero, Simon Amstutz

What does “Mindful Leadership” Mean for the CEO of a Health Tech Start-up – During a Pandemic Era?

Hopp Schwiiz: Switzerland leading Innovation in Europe

Trump's four executive orders to lower drug prices: what does this mean for value-based contracting & innovative drugs?

Corina Sommer, joins Lyfegen Advisory Board

Our new Customer Success Hero: Welcome to the Lyfegen team, Simon Amstutz!

At Lyfegen, the security of patient data is of utmost importance! We are proud to announce that we are ISO 27001 certified, an internationally recognised information security standard!

João Marques-Gomes, PhD, joins Lyfegen Advisory Board

At Lyfegen customers are at the centre of our heart! We are proud to announce that we are ISO 9001:2015 certified!

What is value-based contracting with Lyfegen?

Join Lyfegen's CFO, Michel Mohler, on June 18th at the Basel Area Business & Innovation and Deloitte «DayOne Experts» webinar!

Find us in the first Startup Guide for Switzerland! We were selected as one of the most innovative startups with a clear vision for impact on people and the planet.

Have you voted yet? Vote now for Lyfegen as Swiss Startup 2020!

Professor Jens Grüger, PhD, joins Lyfegen Advisory Board

Melya Hughes Crameri, PhD joins Lyfegen Advisory Board

Lyfegen raises CHF 750‘000 in Seed Capital

Envisioning solutions that solve meaningful real-world problems – meet Andrei Cantea, our new visionary Senior Product Designer